期刊： BREAST CANCER RESEARCH, 2023; 25 (1)
BackgroundBreast cancer is one of the three most common cancers worldwide and is the most common malignancy in women. Treatment approaches for breast ......
期刊： BREAST CANCER RESEARCH, 2023; 25 (1)
BackgroundChemotherapy is an important strategy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+H......
期刊： BREAST CANCER RESEARCH, 2023; 25 (1)
BackgroundBreast cancer (BC) treatments and related symptoms may affect return to work (RTW). The objective of this study was to investigate the impac......
期刊： BREAST CANCER RESEARCH, 2023; 25 (1)
BackgroundCell adhesion is indispensable for appropriate tissue architecture and function in multicellular organisms. Besides maintaining tissue integ......
期刊： BREAST CANCER RESEARCH, 2023; 25 (1)
Background Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have been established as a standard treatment for hormone receptor (HR)-positive, human......
期刊： BREAST CANCER RESEARCH, 2023; 25 (1)
BackgroundElucidating the unique immunoregulatory mechanisms in breast cancer microenvironment may help develop new therapeutic strategies. Some studi......
期刊： BREAST CANCER RESEARCH, 2023; 25 (1)
BackgroundMultiparametric magnetic resonance imaging (MP-MRI) has high sensitivity for diagnosing breast cancers but cannot always be used as a routin......
期刊： BREAST CANCER RESEARCH, 2023; 25 (1)
BackgroundWhen ipsilateral multifocal primary breast cancer (IMBC) is detected, standard routine is to evaluate the largest tumor with immunohistochem......
期刊： BREAST CANCER RESEARCH, 2023; 25 (1)
Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast......
